Maruho entered into an agreement with SkyePharma to develop, market and distribute SkyePharma’s sustained-release formulation of the local anaesthetic bupivacaine, DepoBupivacine™ that is in phase 2 clinical trials for treating post-operative pain. The deal could be worth up to US$18 M to SkyePharma if specific milestones and sales targets are met.